Opill Proposal Makes ACNU Sense, Stakeholders Comment On US 'Additional Conditions' Proposal

As pharma marketing and Rx-to-OTC switch experts told HBW Insight, health care industry stakeholders submitting comments to the FDA connect Opill NDA to FDA’s consideration of an ACNU pathway.